Malvern-based biopharmaceutical company Galera Therapeutics is filing for FDA approval of a new drug. The treatment, avasopasem, helps radiotherapy-induced severe oral mucositis, or painful ulcers in the mouth and throat, writes John George for the Philadelphia Business Journal.  

Currently, there are no FDA-approved treatments. Galera CEO Mel Sorenson said that thousands of people undergoing radiotherapy are at risk for these painful ulcers.  

In addition to treating ulcers, Sorenson said the drug reduces cisplatin-related chronic kidney disease in patients dealing with head and neck-related cancer.  

As of Sept. 30, the 30-employee company had $42.8 million in cash and cash equivalents. After filing for FDA approval, Galera’s shares opened at 9 percent Monday, according to the Philadelphia Business Journal.  

Read more about avasopasem in the Philadelphia Business Journal.